Evidence map›Paper›PMID 25816015›Full record

ArticlePloS one2015

The impact of immunosenescence on humoral immune response variation after influenza A/H1N1 vaccination in older subjects.

Iana H Haralambieva, Scott D Painter, Richard B Kennedy, Inna G Ovsyannikova, Nathaniel D Lambert, Krista M Goergen, Ann L Oberg, Gregory A Poland

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 75 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Journal of preventive medicine and hygiene · 2024
    Article
  13. Article
  14. Immunosenescence: molecular mechanisms and diseases.Signal transduction and targeted therapy · 2023
    Review
  15. Observational
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Iana H HaralambievaMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America.
Scott D PainterMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America.
Richard B KennedyMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America.
Inna G OvsyannikovaMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America.
Nathaniel D LambertMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America.
Krista M GoergenMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Division of Biomedical Statistics and Informatics - Department of Health Science Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Ann L ObergMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Division of Biomedical Statistics and Informatics - Department of Health Science Research, Mayo Clinic, Rochester, Minnesota, United States of America.
Gregory A PolandMayo Vaccine Research Group, Mayo Clinic, Rochester, Minnesota, United States of America; Program in Translational Immunovirology and Biodefense, Mayo Clinic, Rochester, Minnesota, United States of America; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Mayo Clinic in Florida · USMayo Clinic · USWinnMed · US

Funding

Mayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2M
Bioinformatics Approach to Influenza A/H1N1 Vaccine Immune ProfilingU01AI089859 · NIAID · MAYO CLINIC ROCHESTER · PI POLAND, GREGORY A. · 2010 to 2015
$33.8M
NCATS NIH HHS UL1 TR000135NIAID NIH HHS U01 AI089859NIAID NIH HHS U01AI089859
6 · The paper itself

Abstract

backgroundAlthough influenza causes significant morbidity and mortality in the elderly, the factors underlying the reduced vaccine immunogenicity and efficacy in this age group are not completely understood. Age and immunosenescence factors, and their impact on humoral immunity after influenza vaccination, are of growing interest for the development of better vaccines for the elderly.

methodsWe assessed associations between age and immunosenescence markers (T cell receptor rearrangement excision circles - TREC content, peripheral white blood cell telomerase - TERT expression and CD28 expression on T cells) and influenza A/H1N1 vaccine-induced measures of humoral immunity in 106 older subjects at baseline and three timepoints post-vaccination.

resultsTERT activity (TERT mRNA expression) was significantly positively correlated with the observed increase in the influenza-specific memory B cell ELISPOT response at Day 28 compared to baseline (p-value=0.025). TREC levels were positively correlated with the baseline and early (Day 3) influenza A/H1N1-specific memory B cell ELISPOT response (p-value=0.042 and p-value=0.035, respectively). The expression and/or expression change of CD28 on CD4+ and/or CD8+ T cells at baseline and Day 3 was positively correlated with the influenza A/H1N1-specific memory B cell ELISPOT response at baseline, Day 28 and Day 75 post-vaccination. In a multivariable analysis, the peak antibody response (HAI and/or VNA at Day 28) was negatively associated with age, the percentage of CD8+CD28 low T cells, IgD+CD27- naïve B cells, and percentage overall CD20- B cells and plasmablasts, measured at Day 3 post-vaccination. The early change in influenza-specific memory B cell ELISPOT response was positively correlated with the observed increase in influenza A/H1N1-specific HAI antibodies at Day 28 and Day 75 relative to baseline (p-value=0.007 and p-value=0.005, respectively).

conclusionOur data suggest that influenza-specific humoral immunity is significantly influenced by age, and that specific markers of immunosenescence (e.g., the baseline/early expression of CD28 on CD4+ and/or CD8+ T cells and T cell immune abnormalities) are correlated with different humoral immune response outcomes observed after vaccination in older individuals, and thus can be potentially used to predict vaccine immunogenicity.

Indexed as

Immunity, HumoralImmunosenescenceVaccinationAgedAged, 80 and overAge FactorsB-LymphocytesFemaleHumansInfluenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesMaleMiddle AgedTelomeraseTime FactorsInfluenza VaccinesTelomerase

Identifiers

PMID25816015
PMCPMC4376784
OpenAlexW2096706590

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.